In the management of advanced or recurrent endometrial carcinoma with dMMR/MSI-H status, the landmark GARNET trial demonstrated activity of which agent as a single agent?
- A Pembrolizumab (anti-PD-1)
- B Nivolumab (anti-PD-1) plus ipilimumab
- C Lenvatinib plus pembrolizumab combination
- D Dostarlimab (anti-PD-1) ✓
Explanation
The GARNET trial evaluated dostarlimab (anti-PD-1 antibody, TSR-042) as monotherapy in advanced/recurrent endometrial cancer. In the dMMR/MSI-H cohort, overall response rate was ~42% with durable responses (median duration not reached at data cutoff). This led to FDA approval of dostarlimab for dMMR endometrial cancer after prior platinum-based therapy. The KEYNOTE-158 trial similarly showed pembrolizumab activity in MSI-H solid tumors. Lenvatinib + pembrolizumab (from KEYNOTE-775) is used for pMMR endometrial cancer regardless of MSI status. The DUO-E and NRG/GOG study established combination immunotherapy plus platinum in first-line advanced disease. dMMR testing is now standard for all advanced/recurrent endometrial cancers.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.